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Abstract
Background: Current operational diagnostic systems have substantial limitations for lifetime diagnostic
classification of bipolar spectrum disorders. Issues include: (1) It is difficult to operationalize the integration
of diverse episodes of psychopathology, (2) Hierarchies lead to loss of information, (3) Boundaries
between diagnostic categories are often arbitrary, (4) Boundaries between categories usually require a
major element of subjective interpretation, (5) Available diagnostic categories are relatively unhelpful in
distinguishing severity, (6) "Not Otherwise Specified (NOS)" categories are highly heterogeneous, (7)
Subclinical cases are not accommodated usefully within the current diagnostic categories. This latter
limitation is particularly pertinent in the context of the increasing evidence for the existence of a broader
bipolar spectrum than has been acknowledged within existing classifications.
Method: We have developed a numerical rating system, the Bipolar Affective Disorder Dimension Scale,
BADDS, that can be used as an adjunct to conventional best-estimate lifetime diagnostic procedures. The
scale definitions were informed by (a) the current concepts of mood syndrome recognized within DSMIV
and ICD10, (b) the literature regarding severity of episodes, and (c) our own clinical experience. We
undertook an iterative process in which we initially agreed scale definitions, piloted their use on sets of
cases and made modifications to improve utility and reliability.
Results: BADDS has four dimensions, each rated as an integer on a 0 – 100 scale, that measure four key
domains of lifetime psychopathology: Mania (M), Depression (D), Psychosis (P) and Incongruence (I). In
our experience it is easy to learn, straightforward to use, has excellent inter-rater reliability and retains
the key information required to make diagnoses according to DSMIV and ICD10.
Conclusions: Use of BADDS as an adjunct to conventional categorical diagnosis provides a richer
description of lifetime psychopathology that (a) can accommodate sub-clinical features, (b) discriminate
between illness severity amongst individuals within a single conventional diagnostic category, and (c)
demonstrate the similarity between the illness experience of individuals who have been classified into
different disease categories but whose illnesses both fall near the boundaries between the two categories.
BADDS may be useful for researchers and clinicians who are interested in description and classification of
lifetime psychopathology of individuals with disorders lying on the bipolar spectrum.
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During the course of our family-genetic studies of Bipolar
Disorder we became aware of the need for a relatively sim-
ple dimensional rating scheme that can be used to provide
summary measures of several key areas of lifetime psycho-
pathology relevant to characterization of individuals with
Bipolar spectrum illness.
The operational diagnostic systems, such as RDC [1],
DSMIV [2] and ICD10 [3], that have been developed over
the last 30 years are widely used by clinicians and
researchers and have been an important methodological
advance over earlier, non-structured approaches [4].
Although open to a variety of criticisms and unlikely to
map directly onto the pathophysiology of the disorders,
the operational approach is relatively simple, provides
acceptable levels of reliability and is useful for communi-
cation and decision making regarding management,
research and service provision. In most cases the catego-
ries defined are informed by a broad range of research
data and are revised at regular intervals to take account of
new findings and concepts as they emerge.
However, for clinicians and researchers, such as ourselves,
interested in disorders lying within the Bipolar spectrum
there are several problems in using the current systems for
lifetime diagnosis. These include:
1) It is difficult to operationalize the integration of diverse epi-
sodes of psychopathology – The operational systems perform
best for categorizing a discrete, well-delineated single epi-
sode of psychopathology – for example, there are clear-cut
criteria to define episodes of mania and major depression.
However, a lifetime diagnosis requires integration of the
lifetime experience of psychopathology and the criteria
used are much less easy to operationalize, typically requir-
ing judgements about the balance between different types
of episode [4].
2) Hierarchies lead to loss of information – The existence of
explicit, or implicit, hierarchies creates the situation in
which certain symptoms "trump" others. For example, an
individual can have a diagnosis of DSMIV Schizophrenia
despite having had more episodes of mania during his or
her lifetime than another individual with a diagnosis of
Bipolar I Disorder. For those interested in Bipolarity, this
results in a serious loss of important information.
3) Boundaries between diagnostic categories are often arbitrary
– Although there is usually a plausible evidence base and/
or conceptual basis to support the separation into distinct
diagnostic categories, the criteria used to define the
boundaries between categories is almost always arbitrary.
For example, the level of impairment defines the bound-
ary between Bipolar I and II Disorders – it is most implau-
sible that any specific level of impairment could neatly
carve the boundary between distinct disorders. Similarly,
in DSMIV the boundary between Bipolar I Disorder and
Schizoaffective Disorder, Bipolar Type is defined by the
precise timing of occurrence of psychotic symptoms out-
side of an affective episode. Table 1 lists some key diag-
nostic boundaries relating to bipolar spectrum disorders
and the criteria used in making diagnostic decisions at
these boundaries.
4) Boundaries between categories usually require a major ele-
ment of subjective interpretation – Most of the key bounda-
ries for diagnoses within the Bipolar spectrum require
judgements about severity and/or the balance of symp-
tomatology. This substantial subjective element reduces
reliability and, as commonsense suggests and everyone
who has ever participated in formal reliability exercises
knows, cases lying near diagnostic boundaries contribute
most of the diagnostic disagreements.
5) Available diagnostic categories are relatively unhelpful in
distinguishing severity – No distinction is made between an
individual that just meets the threshold for a specific cat-
egory and another individual that has had multiple severe
episodes.
Table 1: Some key boundaries in Bipolar Spectrum Disorders. The table lists some of the important diagnostic boundaries in bipolar 
spectrum disorders and the criteria used in making diagnostic decisions at these boundaries.
Boundary Criteria on which decision based
Major Depression (with Sub-clinical hypomanias) v. Bipolar II Disorder Number and duration of hypomanic-like symptoms
Bipolar I v. Bipolar II Disorder Impairment and duration
Bipolar I v. Schizoaffective Disorder, Bipolar Type Occurrence and timing of psychotic symptoms
Schizophrenia v. Schizoaffective Disorder, Bipolar Type Balance of psychotic and affective symptomsPage 2 of 10
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current diagnostic categories – An individual who has a
DSMIV Diagnosis of Major Depressive Disorder may have
experienced multiple mild sub-hypomanic episodes.
Indeed, it is being increasingly recognized that the bipolar
spectrum extends well beyond the traditional Bipolar I
and II categories and includes many individuals with for-
mal diagnoses of unipolar major depression under cur-
rent operational systems [5,6]. For those interested in
bipolarity this is wasteful of information.
7) "Not Otherwise Specified (NOS)" categories are highly het-
erogeneous – Because of the need for a catch-all category
that can accommodate the set of cases not fitting the other
operational criteria, the NOS categories in operational
systems may include a wide range of types of case ranging
between the mild and the severe. Thus, such categories
provide little information about the lifetime psychopa-
thology of individuals having the diagnosis.
Dimensional classifications offer an alternative to the
conventional categorical approach and have the potential
to address many of the issues listed above [7]. Dimen-
sional classifications are not a new idea but have not in
the past been widely adopted by either the clinical or
research community. Some of the disadvantages, which
have impeded widespread use in clinical and research set-
tings in psychiatry, stem from their relative complexity –
leading to difficulty in use and interpretation in areas such
as communication and decisions regarding management
and services.
No suitable dimensional instrument was already available
for us to use within our own research on bipolar spectrum
disorders. During the course of our ongoing family-based
clinical research projects that involved assessment and
classification of the lifetime experience of psychopathol-
ogy of Bipolar probands and their relatives we, therefore,
developed and piloted a simple dimensional rating
scheme that was informed by the beneficial aspects of cur-
rent operational categorical systems but addressed several
of the limitations inherent in the use of discrete categories
and provides a richer description of each individual's life-
time experience of psychopathology. We describe the
development, structure and characteristics of this system
within the current paper.
Methods
In developing a dimensional scheme our aim was to use a
small number of numerical measures that would usefully
extend the existing diagnostic schemes – specifically, to
retain the key information required to make diagnoses
whilst maximizing the richness of the additional descrip-
tive information and minimizing the problems inherent
in the categorical approach. In using the current classifica-
tions for diagnosis of individuals within the Bipolar spec-
trum, the following key issues are considered within the
decision-making process:
1) The presence and severity of manic syndromes.
2) The presence and severity of depressive syndromes.
3) The presence of psychotic symptoms and the balance of
mood and psychotic symptomatology.
4) The mood congruence of psychotic symptoms and the
temporal relationship between affective and psychotic
symptomatology.
In order to capture information relating to the 4 key issues
above, we, therefore, chose to use 4 dimensions, one for
each issue. Each dimension was set up to provide an
ordered (not necessarily linear) measure of the relevant
lifetime experience of psychopathology for the individual
such that those scoring higher on the scale would have
experienced more clinically important and convincing
psychopathology – typically a mix of severity and fre-
quency/duration. Ranges and anchor points in the scales
were initially decided after discussion by the senior inves-
tigators and informed by (a) the current concepts of sever-
ity and type of mood syndrome recognized within DSMIV
and ICD10, (b) the literature regarding severity of epi-
sodes [8-10], and (c) our own experience in clinical work
and research with patients with bipolar spectrum disor-
ders. We undertook an iterative process in which we ini-
tially agreed scale definitions and rating guidelines,
piloted their use on sets of cases and modified the scale
and guidelines to improve utility and reliability. The scale
– the Bipolar Affective Disorders Dimension Scale,
BADDS – has been under development by our group since
1996 and has gone through several iterations. We describe
the most recent iteration, Version 3.0 which has been used
by our group and collaborators since 1999. All individuals
who were assessed with BADDS as part of the diagnostic
assessment provided written informed consent to partici-
pate in family-genetic studies of mood disorder and our
protocols received approval from relevant ethical review
committees.
Results
Basic structure of BADDS
BADDS comprises four dimensions that provide a quanti-
tative measure of lifetime experience of psychopathology
in each of four domains: Manic-like episodes (the Mania
dimension, M), Depression-like episodes (the Depression
dimension, D), Psychotic symptomatology (the Psychosis
dimension, P) and the relationship (in both congruence
of content and in timing) between psychotic features (if
present) and mood episodes (the Incongruence dimen-Page 3 of 10
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BADDS rating guidelines). Each dimension provides a
composite measure that takes account of both severity
and frequency of relevant psychopathology and is rated
using integers in the range 0 to 100, inclusive. As with
conventional lifetime best-estimate categorical diagnosis,
the dimensional ratings are made on the basis of all avail-
able information – which typically would include semi-
structured lifetime psychiatric interview and review of psy-
chiatric case notes. The criteria used for bipolar spectrum
diagnoses is similar within DSMIV and ICD10. We have
used ICD10 as the primary source for episode definitions
because it provides a clearer differentiation of severity for
depressive episodes. Basic background information and
general rating guidelines are provided in pages 1 and 2 of
the BADDS rating guidelines (see Appendix A). The spe-
cific characteristics of each dimension are described
below.
Mania dimension, M
The severity of the lifetime worst (ie. most severe) episode
of manic spectrum psychopathology identifies a range of
scores on the M dimension to be considered (see table 2
and the rating guidelines for the scale: Appendix A). The
lifetime "amount" of manic spectrum psychopathology
experienced then determines the score within the range
according to clear guidelines that attach weight to the
number and severity of episodes but allow sufficient flex-
ibility that ratings can take account of other factors where
appropriate (such as length of episodes).
Once the range for rating has been decided by considering
the severity of the worst episode, the score is determined
by starting at the lowest score in the range and adding 2
points for each additional episode of equal severity, up to,
but not exceeding, the maximum score in the range. Thus,
an individual who has experienced 7 episodes of incapac-
itating mania would be rated M = 92 (the range is 80–100
with 12 points being added to the initial 80 because there
have been 6 incapacitating episodes over and above the
worst episode that identified the range). Similarly an indi-
vidual who has experienced 3 episodes of hypomania
would be rated as M = 44. An individual who has experi-
enced 50 near-hypomanic episodes (ie. episodes that
closely approach, but do not meet, criteria for hypoma-
nia) would be rated as M = 39. For individuals who (as is
common) have also experienced episodes of lower sever-
ity than the worst ever episode, points can be added – but
with a substantially lower weighting than for additional
episodes at the same severity. Thus, an individual who has
experienced 2 episodes of mania (none incapacitating)
and 10 episodes of hypomania would receive a rating of
M = 67 (the range is 60–79; the worst episode of mania
provides a starting score of 60 to which is added 2 points
for the second manic episode and 5 points for the 10
hypomanic episodes). An individual who has experienced
2 episodes of mania (none incapacitating) and 10 epi-
sodes of near-hypomania would receive a rating of M = 62
or 63 depending upon the judgement of the rater as to the
importance of the near-hypomanic episodes (the range is
60–79; the worst episode of mania provides a starting
score of 60 to which is added 2 points for the second
manic episode and up to one point for the 10 sub-
hypomanic episodes).
Depression dimension, D
The principles for this dimension follow closely those for
the M dimension. The severity of the lifetime worst (ie.
most severe) episode of depression spectrum psychopa-
thology identifies a range of scores on the D dimension to
be considered (see table 3 and the rating guidelines for the
scale: Appendix A). The lifetime "amount" of depression
spectrum psychopathology experienced then determines
the score within the range according to clear guidelines
that attach weight to the number and severity of episodes
and allows sufficient flexibility that ratings can take
account of other factors where appropriate (such as length
of episodes).
Once the range for rating has been specified by consider-
ing the severity of the worst episode, the score is deter-
mined by adding 1 point for each additional episode of
equal severity for the mild and moderate depression
ranges (each of which spans 10 points) and 2 points for
each additional episode of equal severity for the other
ranges (each of which spans 20 points). Thus, an individ-
ual who has experienced 11 or more episodes of incapac-
itating depression would be rated D = 100 (the range is
80–100 with 20 points being added to the initial 80
because there have been 10 or more incapacitating epi-
sodes over and above the worst episode that identified the
range). An individual who has experienced 3 episodes of
moderate depression would be rated as D = 52 (the range
is 50–59 with 2 points being added to the initial 50
because there have been 2 episodes over and above the
worst episode that identified the range). As with the M
dimension, for individuals who have also experienced
episodes of lower severity than the worst ever episode,
points can be added but with a substantially lower weight-
ing than for additional episodes at the same severity.
Psychosis dimension, P
This dimension is concerned with lifetime occurrence of
psychotic and near-psychotic features. It provides a meas-
ure of the proportion of functional psychotic illness in
which psychotic symptoms (delusions, hallucinations,
positive formal thought disorder, catatonia or grossly dis-
organized behaviour) have been present. The rating takes
account of both the number and duration of episodes
with and without psychotic features (see table 4 and thePage 4 of 10
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chotic schizotypal features (specifically the following
DSMIV schizotypal items: ideas of reference; odd beliefs
or magical thinking that influences behaviour and is
inconsistent with sub-cultural norms; unusual perceptual
experiences including bodily illusions; odd thinking and
speech; suspiciousness or paranoid ideation; behaviour or
appearance that is odd eccentric or peculiar), in the
absence of clear-cut psychotic features, can be rated in the
lowest range of the dimension if there have been no clear-
cut psychotic features.
Rating of 0 and 1 have specific definitions. The severity
and amount of relevant psychopathology are rated within
the ranges 2–9 (for near-psychotic features), 10–20 (for
relatively brief single or multiple psychotic features) and
21–100 (for individuals having multiple episodes where
psychotic symptoms are a prominent feature). Thus, an
individual for whom psychotic features have been present
and prominent in each episode of illness would be rated
P = 100 (whether this is a single episode or 20 episodes).
An individual for whom psychotic features have been
present and prominent in one third of episodes of illness
would be rated P = 33. An individual for whom multiple
psychotic features have been present but were brief and
non-prominent would be rated P = 20. An individual who
has never experienced clear-cut psychotic features but has
had frequent near-psychotic features would be rated P = 9,
and such a person who has had only occasional near-psy-
chotic features would be rated P = 2.
Incongruence dimension, I
This dimension is the most complex and provides lifetime
information about the relationship between psychotic
and affective psychopathology, specifically in three areas:
(a) the mood congruence of any psychotic features that
occur, (b) the occurrence of specific symptoms that have
special diagnostic weight in the diagnosis of schizophre-
nia and schizoaffective disorder within current opera-
tional classifications (which we denote for convenience,
the "S set": thought echo, insertion, withdrawal or broad-
casting; passivity experiences; hallucinatory voices giving
running commentary, discussing subject in third person
or originating in some part of the body; bizarre delusions;
catatonia), and (c) the temporal relationship between
mood and psychotic psychopathology (see table 5 and the
rating guidelines for the scale: Appendix A). The dimen-
sion is rated only if the P dimension has been rated at P >
9 (ie. occurrence of definite psychotic symptoms at some
time during lifetime); otherwise, it is left blank.
Table 2: Outline of Mania dimension scale. Table shows key points and ranges on the M dimensions together with the criteria defining 
the ranges. More details including explicit guidelines for ratings can be found in page 3 of the BADDS rating guidelines (Appendix A).
Range on M dimension Criterion defining range
0 No evidence of manic features during lifetime
1–19 Elation or irritability and 1+ associated manic symptoms for a distinct period
20–39 Elation or irritability and 3+ associated manic symptoms for at least 1 day
40–59 At least one hypomanic episode
60–79 At least one manic episode but never experienced a manic episode meeting criteria for "incapacitating 
mania" (as defined in BADDS guidelines)
80–100 At least one manic episode meeting criteria for "incapacitating mania" (as defined in BADDS guidelines)
Table 3: Outline of Depression dimension scale. Table shows key points and ranges on the D dimensions together with the criteria 
defining the ranges. More details including explicit guidelines for ratings can be found in page 4 of the BADDS rating guidelines 
(Appendix A).
Range on D dimension Criterion defining range
0 No evidence of depressive features during lifetime
1 – 19 At least one sub-minor depression episode (as defined in BADDS guidelines)
20–39 At least one minor depression episode (as defined in BADDS guidelines)
40–49 At least one major depression episode of mild severity (as defined in BADDS guidelines)
50–59 At least one major depression episode of moderate severity (as defined in BADDS guidelines)
60–79 At least one major depression episode of severe severity (as defined in BADDS guidelines) but never 
experienced incapacitating depressive episode (as defined in BADDS guidelines).
80–100 At least one incapacitating major depression episode (as defined in BADDS guidelines)Page 5 of 10
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ing affective episodes and for whom the psychotic symp-
toms are mainly, but not exclusively mood congruent,
would be rated I = 10. An individual who has psychotic
features only during affective episodes and for whom the
psychotic symptoms are exclusively mood incongruent,
would be rated I = 40. An individual who has psychotic
features including passivity lasting at least 2 weeks at
some time during the illness and only during affective epi-
sodes would be rated I = 47. An individual who has had
psychotic features for at least 2 weeks outside of an affec-
tive episode on several occasions would be rated I = 70.
Utility of BADDS
Our group has substantial experience in use of BADDS
within the context of lifetime psychiatric assessment in
family-genetic studies of Bipolar Disorder, unipolar
depression and puerperal psychosis. It has been used as
part of the diagnostic procedure in over 1100 patients.
Within our group it has been used by 16 researchers
including psychiatrists, psychologists and sociologists. We
have found it to be user-friendly, simple to learn and
straightforward to incorporate within the usual lifetime
best-estimate consensus procedures.
Reliability studies of BADDS
In order to examine the reliability of BADDS within the
context of our typical spectrum of cases we undertook a
reliability study using written case vignettes containing
interview and case notes data for 20 cases selected as a rep-
resentative sample with a mix of diagnoses from our
ongoing studies of mood disorder. Nine raters with expe-
rience of the conventional lifetime diagnostic process par-
ticipated (2 psychiatrists and 7 psychologists) and made
ratings on the BADDS dimensions. A meeting of all raters
was then held to agree a consensus for each rating that was
then used as the gold standard against which agreements
were measured. Mean agreements, measured by intraclass
correlations, were excellent for all dimensions (M: 0.96;
D: 0.90; P: 0.86; I: 0.89).
Table 4: Outline of Psychosis dimension scale. Table shows key points and ranges on the P dimension together with the criteria defining 
the ranges. More details including explicit guidelines for ratings can be found on page 5 of the BADDS rating guidelines (Appendix A).
Range on P dimension Criterion defining range
0 No evidence of psychotic or near-psychotic schizotypal features
1 Uncertainty about presence of psychotic-spectrum symptoms (ie. Suspected but not definite)
2–9 Presence of near-psychotic schizotypal features but never any clear-cut psychotic symptoms
10–20 Brief, clear-cut psychotic symptoms that are not a prominent feature of the illness
21 – 100 Clear-cut psychotic symptoms that are a prominent feature of one or more episodes of illness
Table 5: Outline of Incongruence dimension scale. Table shows key points and ranges on the I dimension together with the criteria 
defining the ranges. The S set of psychotic symptoms are those recognized as having special weight in the diagnosis of schizophrenia 
and schizoaffective disorder (thought echo, insertion, withdrawal or broadcasting; passivity experiences; hallucinatory voices giving 
running commentary, discussing subject in third person or originating in some part of the body; bizarre delusions; catatonia). More 
details including explicit guidelines for ratings can be found on page 6 of the BADDS rating guidelines (Appendix A).
Range on I dimension Criterion defining range
0–40 Psychotic symptoms occur only during affective episodes and do not include any of the S set.
Rating 0 – virtually completely mood congruent.
Rating 20 – approximate balance between mood congruent and incongruent.
Rating 40 – virtually completely mood incongruent
43 Psychotic symptoms occur only during affective episodes and include one or more of the S set which have not 
definitely been present for 2 weeks.
47 Psychotic symptoms occur only during affective episodes and include one or more of the S set which have definitely 
been present for 2 weeks.
50–59 Psychotic symptoms probably present for at least 2 weeks either side of an affective episode.
Rating 50 – on at least one occasion.
Ratings of 51–59 used to reflect recurrence and/or certainty.
60–100 Psychotic symptoms definitely present for at least 2 weeks either side of an affective episode.
Rating 60 – on at least one occasion.
Rating 80 – on many occasions.
Rating 100 – Psychotic symptoms predominate illness and occur chronically outside (or in absence of) affective 
episodes.Page 6 of 10
(page number not for citation purposes)
BMC Psychiatry 2004, 4:19 http://www.biomedcentral.com/1471-244X/4/19A second exercise was undertaken in order to examine the
performance of BADDS with diagnostically difficult cases.
A different, non-overlapping, set of seven raters (4 psychi-
atrists and 3 psychologists) with experience of the conven-
tional lifetime diagnostic process undertook a reliability
study using written case vignettes containing interview
and case notes data for 20 cases selected from those
recruited for our on going studies of functional psychosis
over-represented with diagnostically challenging cases
representing a mix of diagnoses. Raters made lifetime best
estimate diagnoses according to DSMIV and ICD10 and
ratings on the BADDS dimensions. A meeting of all raters
was then held to agree a consensus for each rating that was
then used as the gold standard against which agreements
were measured. DSMIV consensus diagnoses were Bipolar
I Disorder – 6; Bipolar II Disorder – 3; Bipolar Disorder
Not Otherwise Specified – 3; Schizoaffective Disorder,
Bipolar Type – 2; Recurrent major Depression – 2; Single
episode major depression – 1; Depression Not Otherwise
Specified – 2; Schizophrenia – 1. Mean categorical agree-
ment across raters, measured by Cohen's κ was 0.68 for
DSMIV and 0.62 for ICD10. Mean agreements on the
BADDS dimensions, measured by intraclass correlations
were: M: 0.91; D: 0.86; P: 0.96; I: 0.78.
Prediction of DSMIV and ICD10 diagnoses from dimension 
scores
In order to test the assumption that most of the categorical
diagnostic information is preserved within the dimen-
sions, one rater (NC), experienced in use of BADDS, pre-
dicted diagnoses according to DSMIV and ICD10 based
soley upon the dimension scores on BADDS for 50 repre-
sentative cases selected by LJ from amongst those
recruited for our genetic studies of Bipolar spectrum
mood disorders (both categorical diagnoses and dimen-
sion scores for each case had been made by 2 independent
raters according to best estimate lifetime procedures on
the basis of semi-structured interview and psychiatric case
note data). The sample comprised a mix of cases with
DSMIV categorical diagnoses of Bipolar I Disorder (10),
Bipolar II Disorder (10), Bipolar Disorder Not Otherwise
specified (10), Schizoaffective Disorder (10) and Recur-
rent Major Depressive Disorder (10). Correct prediction
was made for both DSMIV and ICD10 for all cases.
Discussion
We have described a new dimensional rating scheme that
can be used as an adjunct to conventional categorical
diagnosis in order to provide a richer description of some
of the basic features of an individual's lifetime experience
of psychopathology relevant to the bipolar spectrum. The
scheme uses the same data sources as conventional best-
estimate lifetime diagnosis and is straightforward to use at
the same time as the conventional procedure. It retains
several key pieces of information that are lost in the sim-
ple diagnostic process. In particular it avoids hierarchical
loss of information; it retains a measure of severity; it
accommodates sub-clinical cases. We have demonstrated
that it is straightforward to learn and incorporate within
the usual lifetime diagnostic procedures for use by a range
of researchers including those from psychiatry and psy-
chology backgrounds. We have demonstrated excellent
levels of inter-rater agreement even with diagnostically
challenging sets of cases. Further, we have shown that the
key information required for correct diagnostic decisions
according to DSMIV and ICD10 is retained within the
dimensional ratings.
Our group and our collaborators have extensive experi-
ence of use of BADDS as an adjunct to conventional oper-
ational diagnosis and it has been part of our standard
assessment approach for over 5 years. We have found that
it is straightforward to use and adds little to the time taken
to complete the consensus diagnostic process.
For researchers, such as ourselves, wishing to establish a
measure of "caseness" BADDS can easily be used to define
thresholds – for example, a study of mania might require
that cases be included only for M > 64. This would allow
inclusion of all cases with the equivalent of 3 of more epi-
sodes of mania, irrespective of diagnosis. In a study of psy-
chotic Bipolar spectrum illness it might be important to
distinguish between cases in which psychotic features
were a prominent, recurrent feature of illness (rather than
an occasional relatively minor feature). Such individuals
could be selected using BADDS as having P > 50, together
with M > 60. BADDS can also easily be used in conjunc-
tion with categorical diagnoses for case selection.
BADDS was developed within the context of family stud-
ies and it lends itself to providing a substantially more
useful description of the milder ("sub-clinical") end of the
Bipolar spectrum which is frequently encountered within
members of families of probands with full-blown Bipolar
illness. Conventional categorical approaches often lead to
unsatisfactory diagnoses such as "Never ill", "Major
Depressive Disorder" or some form of mild "Not Other-
wise Specified" category when it is clear that there is some
definite, albeit mild, degree of bipolarity. Within the con-
text of family studies it is extremely wasteful to discard
such quantitative information about the presence and
extent of bipolar features and BADDS provides a simple
approach to making simple but efficient use of such data.
Directly related to this issue, there is currently great inter-
est in delineating the breadth and frequency of expression
of the bipolar illness spectrum in the population. Recent
research, championed by Akiskal and Angst, provides evi-
dence that many cases that have been regarded as being
"unipolar major depression" actually have subtle (or notPage 7 of 10
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been suggested that recognize several categories of milder
bipolarity in addition to the conventional DSMIV catego-
ries of Bipolar I and II Disorders [eg. [5]]. BADDS provides
the capability to capture information about this milder
degree of bipolarity – a substantial part of the M dimen-
sions (the range 0 – 39) is available for rating sub-clinical
hypomanic features.
The dimensional approach is particularly beneficial for
cases close to diagnostic boundaries. As any researcher or
clinician knows who has undertaken formal diagnostic
assignment using operational classifications such cases
may be associated with a substantial investment of time in
order to make a finely balanced decision between two (or
occasionally more) discrete diagnostic groups. It is com-
mon that different raters come down on different sides of
the finely balanced decision process leading to a split of
diagnoses with eventual agreement on a consensus but
often with further agreement that it is a "difficult case"
and that the single category chosen does not quite do jus-
tice to the complexity of the case. In contrast, the dimen-
sional approach of BADDS provides a scheme which can
reflect that different ratings of such cases are relatively
close on the quantitative scale. An example is provided by
a case considered in the formal reliability exercise in
which the subject experienced several severe (but not inca-
pacitating) major depressive episodes and also mild recur-
rent sub-hypomanic episodes. Of the 7 raters, 4 made a
diagnosis of DSMIV Bipolar Disorder, Not Otherwise
Specified (the consensus) and 3 a diagnosis of Recurrent
major Depressive Disorder. In contrast the dimensional
ratings were very similar across all raters (means for those
raters making diagnosis of Bipolar Disorder Not Other-
wise Specified: M 27.3; D 70.3; P 0; I blank; means for
those raters making diagnosis of Recurrent Major Depres-
sion: M 23; D 74.7; P 0; I blank).
The primary purpose in developing BADDS was to use it
as an adjunct to better describe some key features of cases
and provide a simple mechanism for case selection on the
basis of these features. BADDS has already been used
within family-based studies to investigate intra-familial
resemblance for lifetime experience of mania and psycho-
sis [11] as well as investigating the relationship between
smoking and psychosis in Bipolar Disorder [12]. We are
currently using BADDS to explore genotype-phenotype
correlations within the context of both classical and
molecular genetic studies of large samples of patients with
functional psychosis and mood disorder.
There are several limitations in use of BADDS, most of
which are common to other lifetime diagnostic proce-
dures. First, and most obvious, is that the ratings are
entirely dependent upon the quality of the data. Poor data
will inevitably lead to poor dimensional ratings as well as
poor categorical diagnoses. It is essential that multiple
data sources are used whenever possible that provide ade-
quate description of an individual's lifetime experience of
psychopathology (not just one or two representative epi-
sodes). As for any type of rating, poor data would be
expected to affect both the validity and reliability of rat-
ings. Second, ratings can only reflect what is known of the
lifetime experience of psychopathology up to the time the
ratings are made. In the light of new episodes of illness
scores on the M and D dimensions may increase; those on
the P and I dimensions may increase or decrease. Third,
subjective judgments are required in integrating multiple
data sources and matching data to the criteria within the
guidelines. Within the context of our current approaches
to psychiatric classification this is inevitable. Judgements
must still be made about the range for a rating – this can
be equivalent to making a categorical judgement, except
that the different categories lie contiguous with one
another on an ordered dimension. Fourth, there are fea-
tures of Bipolar spectrum illness that BADDS was not
designed to capture – examples include the presence and
extent of rapid cycling and the extent of mixed episodes
(although if all manic episodes are mixed this is denoted
in BADDS by adding an "m" qualifier to the M dimension
– see rating guidelines in Appendix A). It is possible for
additional dimensions to be added to capture additional
features. Fifth, BADDS was not developed for use in the
general population. It was designed for use in clinical
populations likely to contain patients with Bipolar spec-
trum diagnoses. The dimensions have meaning in provid-
ing an ordered measure of specific domains of
psychopathology. The distributions remain to be tested in
non-clinical populations but will certainly not conform to
normal distribution. Sixth, for the M and D dimensions
there is a ceiling effect in that these dimensions do not
allow discrimination between individuals having more
than 11 episodes of incapacitating mania, or depression,
respectively. In practice, however, for the populations of
patients that we have studied relatively few patients score
M = 100 or D = 100. Seventh, BADDS is relatively poor at
characterizing cases where the majority of episodes are at
a lower level of severity than the most severe.
Our justification for developing BADSS was that no
dimensional scale was already available that adequately
addressed the issues (1) – (7) discussed in the background
section. However, several researchers have described
approaches relevant to dimensional ratings of psychopa-
thology including bipolar features. Depue has described a
quantitative scale for screening for Bipolar and Unipolar
disorders within a non-clinical university population
[13]. This derived a bipolar and a unipolar dimension
from a modified version of the General behaviour Inven-
tory [14] and focused on screening for affective psychopa-Page 8 of 10
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and colleagues have described a complex procedure for
lifetime psychopathological assessment that includes a
detailed interview schedule and case note review (taking 9
hours per patient) and produces lifetime summary scores
on 30 scales covering a wide range of psychopathology
[15]. One popular approach to lifetime rating of psycho-
pathology for functional psychosis is provided by
OPCRIT, a computer-based 92 item checklist that includes
symptoms over a range of domains including positive,
negative and disorganized psychotic symptoms, course
variables, depressive symptoms and manic symptoms
[16]. OPCRIT can be used in a variety of ways but was pri-
marily developed as a diagnostic system. It performs best
for schizophrenia spectrum disorders, although it can be
used satisfactorily in diagnosis of Bipolar Disorder [17].
However, OPCRIT does not provide a dimensional meas-
ure of severity or frequency/duration of the domains of
psychopathology and, in its unmodified form, is much
less satisfactory for use with disorders having a predomi-
nantly episodic course. However, within these constraints,
OPCRIT has been used by several groups for investigating
factor structures of patient sets with functional psychotic
illness [eg. [18,19]]. Several groups working on the genet-
ics of psychosis have described dimensional approaches
that focus on the psychotic domains of psychopathology.
Maziade et al have examined lifetime ratings of psychotic
symptom dimensions in patients with schizophrenia and
Bipolar Disorder [20]. There was no coverage of mood
symptoms and assessments were confined to predomi-
nant symptoms in acute episodes and predominant symp-
toms "between" episodes. Kendler et al [21] have used
clinical judgement to make ratings on a 4 point scale that
reflected severity and duration for each of 9 symptom and
2 course variables which included depressive symptoms
and manic symptoms. Levinson and colleagues [22] have
recently described a lifetime dimension scale for use in
psychosis research, the Lifetime Dimensions of Psychosis
Scale (LDPS). This was developed within the context of
family-genetic studies of schizophrenia and motivated by
several of the same concerns and aims that motivated us
in developing BADDS. Ratings are made on a 39 item
scale that reflect severity (on a 5 point scale) and duration
(on a 5 point scale) for lifetime occurrence of a range of
psychotic features encompassing positive, bizarre, nega-
tive and disorganized domains plus depressive and manic
syndromes. As with the approach taken by Maziade and
Kendler, the focus of LDPS is schizophrenia spectrum
disorders and a chronic course. There is relatively little
attention to the milder mood psychopathology, episodic
course and to the relationship between mood and psy-
chotic symptomatology. These are all issues of key impor-
tance to study of bipolar spectrum illness and are a focus
of BADDS.
A further useful approach in characterization of episodic
disorders such as Bipolar Disorder is the life chart method
[23] which provides a visual schematic representation of
illness using a time-line on which is charted key events, ill-
ness episodes and treatments during an individual's life.
We find this an invaluable component of our own assess-
ments but it in general it is necessary for quantitative and
qualitative information about illness type, frequency and
severity to abstracted from the life chart for use in research
or clinical settings. BADDS clearly does not provide the
full richness of individual description of the life chart
method but is designed to capture some of the important
features of an individual's lifetime experience of illness.
Finally, it is important to emphasize that BADDS is a
dimensional system developed on the basis of existing
data about the nosology of bipolar spectrum disorders in
order to provide a description of domains recognized as
important in classification. This is an entirely distinct
approach to that of researchers who have undertaken fac-
tor analyses of symptoms during acute episodes of func-
tional psychotic illness – generally identifying factors or
clusters that represent the features of episodes (mania,
depression etc) [eg. [24-26]].
Conclusions
Current operational diagnostic systems have substantial
limitations for classification of bipolar spectrum disor-
ders. We have described a relatively simple dimensional
rating system, BADDS, that can be used as an adjunct to
conventional best-estimate lifetime diagnostic procedures
[27] in order to provide information about four key
domains of lifetime psychopathology: Mania (M),
Depression (D), Psychosis (P) and Incongruence (I). In
our experience BADDS is easy to learn, straightforward to
use, has excellent inter-rater reliability and retains the key
information required to make diagnoses according to
DSMIV and ICD10. Use of BADDS as an adjunct to con-
ventional categorical diagnosis provides a richer descrip-
tion of lifetime psychopathology that (a) can
accommodate sub-clinical features, (b) discriminate
between illness severity amongst individuals within a sin-
gle conventional diagnostic category, and (c) demonstrate
the similarity between the illness experience of individu-
als who have been classified into different disease catego-
ries but whose illnesses both fall near the boundaries
between the two categories. BADDS may be useful for
researchers and clinicians who are interested in descrip-
tion and classification of lifetime psychopathology of
individuals with disorders lying on the bipolar spectrum.
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